Dr. Quanli Gao 高全立
Chief Physician
Department of Biological Immunotherapy, Henan Cancer Hospital, Zhengzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Immunotherapy and comprehensive treatment for malignant tumors, including lung cancer, breast cancer, and esophageal cancer.
Dr. Gao is Chief Physician and Director of the Biological Therapy Department at Henan Cancer Hospital. Dr. Gao holds a medical doctorate and serves as a master’s supervisor. Training includes a degree from Henan Medical University (1992), a master’s in tumor immunology from Cancer Hospital of Chinese Academy of Medical Sciences (1999), and postdoctoral research at Oslo University Hospital (2007–2009). Dr. Gao has received four provincial scientific achievement awards and published over 20 papers.
Professional roles
- Member, Biological Therapy Professional Committee, Chinese Society of Immunology
- Member, Clinical Application Professional Committee, China Medical Biotechnology Association
- Vice Chair, Tumor Biological Therapy Professional Committee, Henan Province
- Director, Henan Anti-Cancer Association
Name order: in Chinese the family name comes first (Gao Quanli). Papers usually list the name as Quanli Gao or Gao Q.
Selected publications
101 papers on PubMed matched by name and affiliation; 47 as first or senior author since 2016. Most recent first- or senior-author papers:
- Chin Med J (Engl), 2026 (senior author): Endogenous glucocorticoids and glucocorticoid receptor signaling: Dual regulators of PD-1/PD-L1 immunotherapy efficacy in the tumor microenvironment. PubMed 41850767
- Front Immunol, 2026 (senior author): Real-world study of SHR-1210 plus apatinib in the treatment of BRAF-negative mucosal melanoma: efficacy, safety and implications of precision medicine. PubMed 42093981
- Sci Rep, 2025 (senior author): The baseline circulating immunophenotype characteristics associate with PD(L)-1 targeted treatment response, irae onset, and prognosis. PubMed 40394154
- J Leukoc Biol, 2025 (senior author): Utility of the neutrophil-to-lymphocyte ratio and the ratio of neutrophil-to-lymphocyte ratio after and before adverse events for differential diagnosis of immune-related adverse events and bacterial infections in cancer patients treated with PD-(L)1 inhibitors. PubMed 40083232
- Transl Oncol, 2024 (senior author): Transient-resting culture after activation enhances the generation of CD8(+) stem cell-like memory T cells from peripheral blood mononuclear cells. PubMed 39357466
- Mol Immunol, 2024 (senior author): Corrigendum to "CD69(+) Vδ1γδ T cells are anti-tumor subpopulations in hepatocellular carcinoma" [Mol. Immunol. 172 (2024) 76-84]. PubMed 39471767
- Photodiagnosis Photodyn Ther, 2024 (senior author): Tongue squamous cell carcinoma treated by 5-aminolevulinic acid administrated through Microdrop method. PubMed 39153711
- Mol Immunol, 2024 (senior author): CD69(+) Vδ1γδ T cells are anti-tumor subpopulations in hepatocellular carcinoma. PubMed 38917598
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion